NGM-936

N/A

Report date: 2026/03/19 16:57:27

Base Information

Drug NameNGM-936

Drug Alias Nameanti-CD3/anti-ILT3 bispecific T-cell engager (NGM Biopharmaceuticals)NGM-936

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily A member 4 modulatorsT cell surface glycoprotein CD3 modulators

TargetsLeukocyte immunoglobulin-like receptor subfamily A member 4T cell surface glycoprotein CD3

Therapy Area/IndicationsMultiple MyelomaLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNGM Biopharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesNGM Biopharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A